

30

APR-21-2004 14:59

P&G HC PATENT DIV.

Procter & Gamble - I.P. Division

JCWSCS 2 1 APR 2004

FILE COPY 513 622 3300 P.01/05

IMPORTANT CONFIDENTIALITY NOTICE

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.


**FACSIMILE TRANSMITTAL SHEET AND
CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8**

TO: United States Patent and Trademark Office

Fax No. (703) 746-9195

Phone No.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on April 21, 2004, to the above-identified facsimile number.

 (Signature)

FROM: Jennifer L. Livingston

Fax No. (513) 622-3300

Phone No. (513) 622-3954

Number of Pages Including this Page: 5

Listed below are the item(s) being submitted with this Certificate of Transmission:

- 1) Request for Correction of Filing Receipt (1 page)
- 2) Copy of 1st page of application listing cross reference information (1 page)
- 3) Filing Receipt with correction noted (2 pages)

Inventor(s): Michael George Natchus et al.

S.N.: 10/730,572

Filed: December 8, 2003

Case: 6229MRR

Comments:

P&G Case 6229MRR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :
Michael George Natchus, et al. : Confirmation No. 3064
Serial No. 10/730,572 : Group Art Unit 1614
Filed December 8, 2003 : Examiner

For Substituted Cyclic Amine Metalloprotease Inhibitors

REQUEST FOR CORRECTION OF FILING RECEIPT

Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Applicants hereby request a corrected filing receipt. Attached is a copy of the Filing Receipt with the changes noted thereon. Specifically, there is an error in the filing date associated with the first listed cross-reference. The correct filing date for CIP Application No. 10/186,531, as shown on the first page of the filed application (copy attached) is October 1, 2003. The updated filing receipt, mailing date 04/06/2004, lists the date as 07/01/2002. Please make the following correction:

Please omit "07/01/2002" and insert therefore - 10/01/2003 --.

Applicants submit that the error was not the fault of the Applicants. Accordingly, no fee is believed to be due.

Respectfully submitted,

By



Mary Pat McMahon
Attorney or Agent for Applicants
Registration No. 34,673
Tele. No. (513) 622-5502

Date: April 21, 2004

Customer No. 27752



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/730,572	12/08/2003	1614	900	6229MRR		12	3

CONFIRMATION NO. 3064

27752

THE PROCTER & GAMBLE COMPANY
INTELLECTUAL PROPERTY DIVISION
WINTON HILL TECHNICAL CENTER - BOX 161
6110 CENTER HILL AVENUE
CINCINNATI, OH 45224

UPDATED FILING RECEIPT



OC000000012289842

Date Mailed: 04/06/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Michael George Natchus, Alpharetta, GA;
Biswanath De, Cincinnati, OH;
Stanislaw Pikul, Germantown, MD;
Neil Gregory Almstead, Holmdel, NJ;
Roger Gunnard Bookland, Cincinnati, OH;
Yetunde Olabisi Taiwo, West Chester, OH;
Menyan Cheng, West Chester, OH;

CENTRAL DOCKETING	
Atty/GBU Contact: <i>JLL/KLP</i>	
DATE REC'D	APR 8 2004
<input type="checkbox"/> FAX	<input checked="" type="checkbox"/> MAIL

Domestic Priority data as claimed by applicant

This application is a CIP of 10/186,531 07/01/2002 * 10/01/2003
which is a CIP of 09/888,675 06/25/2001 PAT 6,569,855
and is a CIP of 09/888,759 06/25/2001 ABN
which is a DIV of 08/918,317 08/26/1997 PAT 6,417,219
which claims benefit of 60/024,842 08/28/1996
(*Data provided by applicant is not consistent with PTO records.

Foreign Applications

If Required, Foreign Filing License Granted: 03/10/2004

Projected Publication Date: 07/15/2004

Non-Publication Request: No

Early Publication Request: No

Title

Substituted cyclic amine metalloprotease inhibitors

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

6229MRR

SUBSTITUTED CYCLIC AMINE METALLOPROTEASE INHIBITORS

Michael George Natchus
Biswanath (NMN) De
Stanislaw (NMN) Pikul
Neil Gregory Almstead
Roger Gunnard Bookland
Yetunde Olabisi Taiwo
Menyan (NMN) Cheng

CROSS REFERENCE

This is a Continuation-in-Part Application of Application No. 10/186,531, filed October 1, 2003, which is a Continuation-in-Part of Application Nos. 09/888,675 and 09/888,759 filed concurrently on June 25, 2001, which are Divisionals of US Application No. 08/918,317, filed August 26, 1997 which claim priority under Title 35, United States Code 119(e) from Provisional Application Serial No. 60/024,842, filed August 28, 1996.

TECHNICAL FIELD

This invention is directed to compounds which are useful in treating diseases associated with metalloprotease activity, particularly zinc metalloprotease activity.

BACKGROUND**Background**

A number of structurally related metalloproteases [MPs] effect the breakdown of structural proteins. These metalloproteases often act on the intercellular matrix, and thus are involved in tissue breakdown and remodeling. Such proteins are referred to as metalloproteases or MPs. There are several different families of MPs, classified by sequence homology. Several families of known MPs, as well as examples thereof, are disclosed in the art.

These MPs include Matrix-Metallo Proteases [MMPs], zinc metalloproteases, many of the membrane bound metalloproteases, TNF converting enzymes, angiotensin-converting enzymes (ACEs), disintegrins, including ADAMs (See Wolfsberg et al, 131 *J. Cell Bio.* 275-78 October, 1995), and the enkephalinases. Examples of MPs include human skin fibroblast collagenase, human skin fibroblast gelatinase, human sputum collagenase, aggrecanase and gelatinase, and human stromelysin. Collagenase, stromelysin, aggrecanase and related enzymes are thought to be important in mediating the symptomatology of a number of diseases.

Many potential therapeutic indications of MP inhibitors have been discussed in the literature. For example, coronary artery disease affects 57.5 million people in the United States, alone, annually claiming the lives of approximately one million individuals. The primary instigator leading to the characteristic sequelae of coronary artery disease is atherosclerosis. Atherosclerosis is a complex interaction between lipids and other elements in the blood, and the